New & Upcoming FDA-Approved Peptides
Which peptides were recently approved, and which are still in trials? Here is the honest 2026 picture — with a clear line between what is approved and what is not yet.
Medically reviewed by Charles Kamen, MD, board-certified neurologist ·
“What are the new FDA-approved peptides?” splits into two honest questions: what has actually been approved recently, and what is still being tested. The two get blurred constantly — often on purpose, by sellers who want a trial-stage name to sound like it is available. It is not.
On the recently approved side, the headline is the GLP-1 and incretin class. Tirzepatide was approved for type 2 diabetes (Mounjaro, 2022) and then for chronic weight management (Zepbound, 2023), joining semaglutide (Ozempic 2017, Wegovy 2021). These are the newest peptides that are genuinely FDA-approved and prescribable today. Because approvals and label expansions keep happening, we track the live status on our peptide regulatory tracker rather than freezing a date here.
On the not-yet-approvedside sits an active pipeline of investigational peptides. These are real, serious drug-development programs — but “in trials” is not “approved,” and until the FDA reviews the data, none of them can be prescribed as standard care.
Late-Stage Pipeline — Not Yet Approved
Reviewed by Charles Kamen, MD. This table reflects publicly reported late-stage development and is not a prediction of approval — outcomes depend on trial results and FDA review. We do not offer investigational peptides outside a legitimate trial, and we do not source “research” versions of them. For the mechanism-by-mechanism picture see our semaglutide vs. tirzepatide vs. retatrutide comparison.
Physician-Led in Las Vegas
Waiting on a “new” peptide — but want results now?
The newest approved options — semaglutide and tirzepatide — are available today after a medical evaluation, with strong trial evidence behind them. An $88 evaluation with Dr. Charles Kamen, MD covers what is approved, what is still in trials, and what actually fits your goals — no hype, no “research” vials.
New Peptides FAQ
What new peptides has the FDA approved recently?
The most significant recent additions are in the GLP-1 / incretin class. Tirzepatide was approved for type 2 diabetes as Mounjaro (2022) and for chronic weight management as Zepbound (2023), and semaglutide (Wegovy) has expanded beyond weight and diabetes. Because approvals and label expansions happen continuously, we keep the live status on our peptide regulatory tracker rather than freezing a date on this page.
What peptides will be FDA-approved next?
No one can promise which will be approved or when — approval depends on trial results and FDA review. The most-watched peptides in late-stage development are retatrutide (a triple agonist), survodutide, CagriSema, and cagrilintide, all studied mainly for obesity and metabolic disease. They are investigational and cannot be prescribed as standard care until and unless the FDA approves them.
Is retatrutide FDA-approved yet?
No. As of July 2026, retatrutide is investigational and still in late-stage clinical trials. It cannot be dispensed as a standard prescription anywhere in the U.S., including Las Vegas. Any product sold as "retatrutide" outside a clinical trial is not an FDA-approved drug. See our physician-reviewed retatrutide guide for current status.
Can I get a "new" peptide before it is FDA-approved?
The only legitimate way to access an investigational peptide before approval is by enrolling in a clinical trial. Products sold online as "the newest peptide" are not early access to an approved drug — they are unregulated research chemicals, not legal or safe for human use. The responsible path is physician evaluation and FDA-approved or legally compounded options.
How do I keep up with new peptide approvals?
We maintain a live peptide regulatory tracker that reflects current approval and compounding status, and this page summarizes the recently approved and late-stage-development picture. Because the FDA landscape shifts, we verify status at the time of care rather than relying on a static list.
Are the new weight-loss peptides better than semaglutide?
That is exactly what the ongoing trials are testing, and it is not settled. Some investigational agents have shown larger average weight loss in trials, but head-to-head evidence, long-term safety, and real-world results are still being established — and none of that matters clinically until a drug is approved. For approved options available now, semaglutide and tirzepatide remain the standard, and Dr. Kamen can walk through which fits you.
Related reading: Peptide regulatory tracker · Which peptides are FDA-approved? · Retatrutide FDA status · Semaglutide vs. tirzepatide vs. retatrutide
Ready to start your longevity care?
Book your $88 evaluation with Dr. Kamen today, online, by phone, or by text.
Book Your $88 EvaluationPrefer to talk? Call (702) 808-2650 or text us to book.
Physician-led peptide therapy in Las Vegas. Visit our clinicAlso serving Henderson — or explore semaglutide weight loss in Las Vegas.